Search

Your search keyword '"McGrath, Julie"' showing total 130 results
Start Over Author "McGrath, Julie"
130 results on '"McGrath, Julie"'

1. Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck.

Author

Leddon, Jennifer L, Gulati, Shuchi, Haque, Sulsal, Allen, Casey, Palackdharry, Sarah, Mathews, Maria, Kurtzweil, Nicky, Riaz, Muhammed Kashif, Takiar, Vinita, Nagasaka, Misako, Patil, Yash, Zender, Chad, Tang, Alice, Cervenka, Brian, McGrath, Julie, Korn, W Michael, Hinrichs, Benjamin H, Jandarov, Roman, Harun, Nusrat, Sukari, Ammar, and Wise-Draper, Trisha M

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Dental/Oral and Craniofacial Disease, Rare Diseases, Clinical Research, Clinical Trials and Supportive Activities, Cancer, Patient Safety, Evaluation of treatments and therapeutic interventions, 6.4 Surgery, 6.1 Pharmaceuticals, Good Health and Well Being, B7-H1 Antigen, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Humans, Neoplasm Recurrence, Local, Nivolumab, Squamous Cell Carcinoma of Head and Neck, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

PurposeLocoregional relapse in patients with head and neck squamous cell carcinoma (HNSCC) is common, approaching 50% for some subsites despite multimodality therapy. Salvage surgery is the standard of care, but able to achieve durable control in only a minority of patients. While adjuvant radiotherapy or chemo-radiotherapy is offered to select patients, this approach can be prohibitively toxic. Given the activity and tolerability of programmed death-1 inhibitors in metastatic HNSCC, we investigated the safety and efficacy of adjuvant nivolumab after salvage surgical resection.Patients and methodsThis was an open-label, multi-institutional phase II clinical trial (NCT03355560). Patients with recurrent, resectable HNSCC were enrolled within 6 weeks of salvage surgery. Six 28-day cycles of adjuvant nivolumab were planned. The primary endpoint was 2-year disease-free survival (DFS) more than 58%, based on an institutional historical control group of 71 patients with recurrent HNSCC who underwent salvage surgery.ResultsBetween February 2018 and February 2020, 39 patients were enrolled. At a median follow-up of 22.1 months, 2-year DFS was 71.4% [95% confidence interval (CI), 57.8-88.1] and the 2-year overall survival (OS) was 73% (95% CI, 58-91.8). Three of 39 (8%) patients experienced grade 3 treatment-related adverse events and 3 of 39 (8%) discontinued treatment due to side effects. Ten of 39 had locoregional recurrence, while 2 of 10 also had synchronous metastatic disease. There was no difference in DFS between PD ligand-1 (PD-L1)-positive and PD-L1-negative patients. There was a nonsignificant trend toward improved DFS in patients with high tumor mutational burden (P = 0.083).ConclusionsAdjuvant nivolumab after salvage surgery in locally recurrent HNSCC is well tolerated and showed improved DFS compared with historical controls.

Published
2022

3. Progressive collapse

Author

McGrath, Julie J.

Subjects
BUILDING AND CONSTRUCTION - Safety Measures, BUILDING AND CONSTRUCTION - Design, TERRORISM - Safety Measures, FORCE AND ENERGY, BLAST-RESISTANT MATERIALS
Abstract

illus

Published
2004

9. Supplementary Table 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 1 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

12. Data from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, primary, Elliott, Andrew, primary, Arnoff, Taylor E., primary, McGrath, Julie, primary, Xiu, Joanne, primary, Walker, Phillip, primary, Bergom, Hannah E., primary, Day, Abderrahman, primary, Ahmed, Shihab, primary, Tape, Sydney, primary, Makovec, Allison, primary, Ali, Atef, primary, Shaker, Rami M., primary, Toye, Eamon, primary, Passow, Rachel, primary, Lozada, John R., primary, Wang, Jinhua, primary, Lou, Emil, primary, Mouw, Kent W., primary, Carneiro, Benedito A., primary, Heath, Elisabeth I., primary, McKay, Rana R., primary, Korn, W. Michael, primary, Nabhan, Chadi, primary, Ryan, Charles J., primary, and Antonarakis, Emmanuel S., primary

Published
2023
Full Text
View/download PDF

16. Metastatic Prostate Cancers with BRCA2 versus ATM Mutations Exhibit Divergent Molecular Features and Clinical Outcomes

Author

Hwang, Justin, primary, Shi, Xiaolei, additional, Elliott, Andrew, additional, Arnoff, Taylor E., additional, McGrath, Julie, additional, Xiu, Joanne, additional, Walker, Phillip, additional, Bergom, Hannah E., additional, Day, Abderrahman, additional, Ahmed, Shihab, additional, Tape, Sydney, additional, Makovec, Allison, additional, Ali, Atef, additional, Shaker, Rami M., additional, Toye, Eamon, additional, Passow, Rachel, additional, Lozada, John R., additional, Wang, Jinhua, additional, Lou, Emil, additional, Mouw, Kent W., additional, Carneiro, Benedito A., additional, Heath, Elisabeth I., additional, McKay, Rana R., additional, Korn, W. Michael, additional, Nabhan, Chadi, additional, Ryan, Charles J., additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

21. Supplementary Table from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Author

Leddon, Jennifer L., primary, Gulati, Shuchi, primary, Haque, Sulsal, primary, Allen, Casey, primary, Palackdharry, Sarah, primary, Mathews, Maria, primary, Kurtzweil, Nicky, primary, Riaz, Muhammed Kashif, primary, Takiar, Vinita, primary, Nagasaka, Misako, primary, Patil, Yash, primary, Zender, Chad, primary, Tang, Alice, primary, Cervenka, Brian, primary, McGrath, Julie, primary, Korn, W. Michael, primary, Hinrichs, Benjamin H., primary, Jandarov, Roman, primary, Harun, Nusrat, primary, Sukari, Ammar, primary, and Wise-Draper, Trisha M., primary

Published
2023
Full Text
View/download PDF

22. Data from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

23. Supplementary Figure 3 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 4 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Figure 5 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Movie 1 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure from Phase II Trial of Adjuvant Nivolumab Following Salvage Resection in Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck

Author

Leddon, Jennifer L., primary, Gulati, Shuchi, primary, Haque, Sulsal, primary, Allen, Casey, primary, Palackdharry, Sarah, primary, Mathews, Maria, primary, Kurtzweil, Nicky, primary, Riaz, Muhammed Kashif, primary, Takiar, Vinita, primary, Nagasaka, Misako, primary, Patil, Yash, primary, Zender, Chad, primary, Tang, Alice, primary, Cervenka, Brian, primary, McGrath, Julie, primary, Korn, W. Michael, primary, Hinrichs, Benjamin H., primary, Jandarov, Roman, primary, Harun, Nusrat, primary, Sukari, Ammar, primary, and Wise-Draper, Trisha M., primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 2 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

30. Supplementary Table 1 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

31. Supplementary Movie 2 from Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., primary, Wang, Mengdie, primary, McGrath, Julie E., primary, Ingabire, Nadia, primary, Hinton, James P., primary, Marr, Kendra D., primary, Simpson, Skyler J., primary, Nagle, Raymond B., primary, Miranti, Cindy K., primary, Warfel, Noel A., primary, Garcia, Joe G.N., primary, Arif-Tiwari, Hina, primary, and Cress, Anne E., primary

Published
2023
Full Text
View/download PDF

32. Abstract HER2-12: HER2-12 Genomic and Transcriptomic Landscape of HER2-Low Breast Cancer

Author

Bansal, Rani, primary, McGrath, Julie, additional, Walker, Phil, additional, Bustos, Matias A., additional, Rodriguez, Estelamari, additional, Sammons, Sarah L., additional, Accordino, Melissa K., additional, Meisel, Jane, additional, Gatti-Mays, Margaret, additional, Hsu, Emily, additional, Lathrop, Kate I., additional, Kaklamani, Virginia, additional, Oberley, Matthew, additional, Korn, W. Michael, additional, and Graff, Stephanie L., additional

Published
2023
Full Text
View/download PDF

33. Clinical and molecular features of ATM and BRCA2 mutations in metastatic prostate cancer.

Author

Shi, Xiaolei, primary, Hwang, Justin, additional, McGrath, Julie, additional, Bergom, Hannah E., additional, Day, Abderrahman, additional, Toye, Eamon, additional, Passow, Rachel, additional, Tape, Sydney, additional, Makovec, Allison, additional, Lozada, John R, additional, Ryan, Charles J., additional, Carneiro, Benedito A., additional, McKay, Rana R., additional, Nabhan, Chadi, additional, Korn, W. Michael, additional, and Antonarakis, Emmanuel S., additional

Published
2023
Full Text
View/download PDF

34. Phase 2 trial of adjuvant nivolumab following salvage resection in patients with recurrent squamous cell carcinoma of the head and neck

Author

Leddon, Jennifer L., Gulati, Shuchi, Haque, Sulsal, Allen, Casey, Palackdharry, Sarah, Mathews, Maria, Kurtzweil, Nicky, Riaz, Muhammed Kashif, Takiar, Vinita, Nagasaka, Misako, Patil, Yash, Zender, Chad, Tang, Alice, Cervenka, Brian, McGrath, Julie, Korn, W. Michael, Hinrichs, Benjamin H., Jandarov, Roman, Harun, Nusrat, Sukari, Ammar, and Wise-Draper, Trisha M.

Subjects
Nivolumab, Head and Neck Neoplasms, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Humans, Neoplasm Recurrence, Local, Article, B7-H1 Antigen
Abstract

Locoregional relapse in patients with head and neck squamous cell carcinoma (HNSCC) is common, approaching 50% for some subsites despite multimodality therapy. Salvage surgery is the standard of care, but able to achieve durable control in only a minority of patients. While adjuvant radiotherapy or chemo-radiotherapy is offered to select patients, this approach can be prohibitively toxic. Given the activity and tolerability of programmed death-1 inhibitors in metastatic HNSCC, we investigated the safety and efficacy of adjuvant nivolumab after salvage surgical resection.This was an open-label, multi-institutional phase II clinical trial (NCT03355560). Patients with recurrent, resectable HNSCC were enrolled within 6 weeks of salvage surgery. Six 28-day cycles of adjuvant nivolumab were planned. The primary endpoint was 2-year disease-free survival (DFS) more than 58%, based on an institutional historical control group of 71 patients with recurrent HNSCC who underwent salvage surgery.Between February 2018 and February 2020, 39 patients were enrolled. At a median follow-up of 22.1 months, 2-year DFS was 71.4% [95% confidence interval (CI), 57.8-88.1] and the 2-year overall survival (OS) was 73% (95% CI, 58-91.8). Three of 39 (8%) patients experienced grade 3 treatment-related adverse events and 3 of 39 (8%) discontinued treatment due to side effects. Ten of 39 had locoregional recurrence, while 2 of 10 also had synchronous metastatic disease. There was no difference in DFS between PD ligand-1 (PD-L1)-positive and PD-L1-negative patients. There was a nonsignificant trend toward improved DFS in patients with high tumor mutational burden (P = 0.083).Adjuvant nivolumab after salvage surgery in locally recurrent HNSCC is well tolerated and showed improved DFS compared with historical controls.

Published
2022

35. Abstract 5793: Comprehensive characterization of FGF/FGFR alterations in invasive breast cancers

Author

Gaur, Kush C., primary, Tiu-Lim, Justin, additional, McGrath, Julie, additional, Walker, Phil, additional, Korn, Michael, additional, Xiu, Joanne, additional, Heeke, Arielle, additional, Kaklamani, Virginia, additional, Tan, Antoinette, additional, Lu, Janice, additional, Spicer, Darcy, additional, Roussos-Torres, Evanthia, additional, Jayachandran, Priya, additional, Saghian, Audrey, additional, Goldkorn, Amir, additional, and Kang, Irene, additional

Published
2022
Full Text
View/download PDF

36. Molecular correlates of Delta-like-ligand 3 (DLL3) expression in neuroendocrine neoplasms (NENs).

Author

Hwang, Justin, primary, McGrath, Julie, additional, Lozada, John R, additional, Brodskiy, Pavel, additional, Xiu, Joanne, additional, Wei, Shuanzeng, additional, Heath, Elisabeth I., additional, Carneiro, Benedito A., additional, Lou, Emil, additional, Soares, Heloisa P., additional, McKay, Rana R., additional, Antonarakis, Emmanuel S., additional, Ryan, Charles J., additional, Spetzler, David, additional, and Beltran, Himisha, additional

Published
2022
Full Text
View/download PDF

40. Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes

Author

Shaikh, Hira, primary, McGrath, Julie E., additional, Hughes, Brittany, additional, Xiu, Joanne, additional, Brodskiy, Pavel, additional, Sukari, Ammar, additional, Darabi, Sourat, additional, Ikpeazu, Chukwuemeka, additional, Nabhan, Chadi, additional, Korn, Wolfgang Michael, additional, and Wise-Draper, Trisha M., additional

Published
2021
Full Text
View/download PDF

42. Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.

Author

Kim, Chul, primary, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, Nagasaka, Misako, additional, Ma, Patrick C., additional, Nieva, Jorge J., additional, Lopes, Gilberto, additional, Borghaei, Hossein, additional, Ikpeazu, Chukwuemeka, additional, Owonikoko, Taofeek K., additional, Demeure, Michael J., additional, Wozniak, Antoinette J., additional, Nabhan, Chadi, additional, Korn, Wolfgang Michael, additional, and Liu, Stephen V., additional

Published
2021
Full Text
View/download PDF

43. Genomic characterization of p16+ compared to p16- HNSCC patients treated with immune checkpoint inhibitors and overall survival.

Author

Shaikh, Hira Ghazal, primary, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, Hughes, Brittany Nicole, additional, Sukari, Ammar, additional, Nabhan, Chadi, additional, Korn, Wolfgang Michael, additional, Darabi, Sourat, additional, Grover, Punita, additional, Chernock, Rebecca, additional, Ikpeazu, Chukwuemeka, additional, and Wise-Draper, Trisha Michel, additional

Published
2021
Full Text
View/download PDF

44. Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.

Author

Ryan, Charles J., primary, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, Hwang, Justin, additional, Nabhan, Chadi, additional, De Souza, Andre Luiz, additional, Barata, Pedro C., additional, Gulati, Shuchi, additional, Wei, Shuanzeng, additional, Merchan, Jaime R., additional, Rao, Arpit, additional, Geynisman, Daniel M., additional, Abuali, Inas, additional, Korn, Wolfgang Michael, additional, and Heath, Elisabeth I., additional

Published
2021
Full Text
View/download PDF

45. Comprehensive genomic profiling and immune characterization of adenoid cystic carcinoma.

Author

Grover, Punita, primary, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, Nabhan, Chadi, additional, Choe, Jennifer Hsing, additional, Chernock, Rebecca, additional, Ikpeazu, Chukwuemeka, additional, Shaikh, Hira Ghazal, additional, Sukari, Ammar, additional, Tang, Alice L, additional, Korn, Wolfgang Michael, additional, and Wise-Draper, Trisha Michel, additional

Published
2021
Full Text
View/download PDF

46. Molecular profiling and survival outcomes of p16+ compared to p16- oropharynx squamous cell cancer patients.

Author

Hughes, Brittany Nicole, primary, Shaikh, Hira Ghazal, additional, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, Sukari, Ammar, additional, Korn, Wolfgang Michael, additional, Nabhan, Chadi, additional, Grover, Punita, additional, Darabi, Sourat, additional, Chernock, Rebecca, additional, Ikpeazu, Chukwuemeka, additional, and Wise-Draper, Trisha Michel, additional

Published
2021
Full Text
View/download PDF

47. Treatment outcomes of recurrent and metastatic adenoid cystic carcinoma: A retrospective analysis.

Author

McGrath, Julie Elaine, primary, Grover, Punita, additional, Xiu, Joanne, additional, Nabhan, Chadi, additional, Choe, Jennifer Hsing, additional, Chernock, Rebecca, additional, Ikpeazu, Chukwuemeka, additional, Shaikh, Hira Ghazal, additional, Sukari, Ammar, additional, Tang, Alice L, additional, Korn, Wolfgang Michael, additional, and Wise-Draper, Trisha Michel, additional

Published
2021
Full Text
View/download PDF

48. Characterization of microsatellite instability (dMMR/MSI-H) and mutational landscape in a large contemporary cohort of upper tract urothelial cancer (UTUC) patients.

Author

Rao, Arpit, primary, McGrath, Julie Elaine, additional, Xiu, Joanne, additional, De Souza, Andre Luiz, additional, Gulati, Shuchi, additional, Abuali, Inas, additional, Sagaram, Smitha, additional, Nabhan, Chadi, additional, Korn, W. Michael, additional, Ryan, Charles J., additional, and Heath, Elisabeth I., additional

Published
2021
Full Text
View/download PDF

49. Who built the built environment? Artifacts, politics, and urban technology

Author

McGrath, Julie J.

Subjects
Urban ecology -- Evaluation, Technology and civilization -- Portrayals, Industry -- Social aspects, Anthropology/archeology/folklore, High technology industry, History
Abstract

Written scholarship on the issue of urban technology and its role in the evolution of American culture are abundant and diverse in both scope and subject matter. The interdisciplinary attempts of writers such as Ruth Cowan, John Fairfield, and Mark Rose succeed in illustrating how the hardware of urban technology are transformed into artifacts whose use and design reflect the values of their social milieu.

Published
1997

50. Gene Editing of α6 Integrin Inhibits Muscle Invasive Networks and Increases Cell–Cell Biophysical Properties in Prostate Cancer

Author

Rubenstein, Cynthia S., primary, Gard, Jaime M.C., additional, Wang, Mengdie, additional, McGrath, Julie E., additional, Ingabire, Nadia, additional, Hinton, James P., additional, Marr, Kendra D., additional, Simpson, Skyler J., additional, Nagle, Raymond B., additional, Miranti, Cindy K., additional, Warfel, Noel A., additional, Garcia, Joe G.N., additional, Arif-Tiwari, Hina, additional, and Cress, Anne E., additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results